MRK - Merck & Co., Inc.
82.15 +0.16 (0.20%)
Pre-Market: 4:38AM EDT
| Previous Close | 82.61 |
| Open | 82.45 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1200 |
| Day's Range | 81.69 - 82.45 |
| 52 Week Range | 66.10 - 87.35 |
| Volume | 5,906,070 |
| Avg. Volume | 9,791,773 |
| Market Cap | 210.027B |
| Beta (3Y Monthly) | 0.32 |
| PE Ratio (TTM) | 23.00 |
| EPS (TTM) | 3.57 |
| Earnings Date | Oct 29, 2019 |
| Forward Dividend & Yield | 2.20 (2.66%) |
| Ex-Dividend Date | 2019-09-13 |
| 1y Target Est | 96.33 |
- Yahoo Finance Video
What's next for Purdue Pharma after filing for bankruptcy
Oxycontin maker Purdue Pharma filed for chapter 11 bankruptcy on Sunday, after reaching a tentative settlement with 24 states that accused the company of fueling the U.S. opioid crisis. Yahoo Finance's Alexis Keenan reports. William Soilman, Chairman and CEO of the Accreditation Council for Medical Affairs, further discusses with Yahoo Finance's Adam Shapiro and Julie Hyman.
- American City Business Journals
A look inside Merck's new Peninsula research 'superhub'
Merck's new facility in South San Francisco is designed to showcase the best the Bay Area biotech community has to offer — both internally as it consolidates staff there and externally as it seeks a bridge to young, innovative companies.
- Zacks
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
- Zacks
Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert
The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.
- InvestorPlace
3 Big Stock Charts for Monday: Merck, Facebook and Microsoft
The market didn't end last week on a high note, but then again, it didn't need to. Even with Friday's 0.07% setback for the S&P 500, the index still mustered just a little less than a 1% advance for the five-day stretch. That makes a third winning week in a row.Source: Shutterstock Oversized Apple (NASDAQ:AAPL) is the reason the broad market could get up and over the hump, falling nearly 2% in Friday's action after investors rethought the costs related to the company's strategy of attracting people to its hardware and new streaming service. That impact was more than smaller names like General Electric (NYSE:GE) could offset. GE was up nearly 1% on the last day of last week, buoyed by optimism surrounding what should amount to a $5 billion debt reduction, funded by asset sales. * 10 Recession-Resistant Services Stocks to Buy As for names worth exploring as Monday's action gets going, however, the stock charts of Facebook (NASDAQ:FB), Microsoft (NASDAQ:MSFT) and Merck (NYSE:MRK) are of the most interest. Here's why.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Microsoft (MSFT)There's no denying Microsoft shares have been one of the market's best and most reliable performers for years now. Even the headwind that hammered most names late last year wasn't horrific for MSFT stock, and shares recovered quite nicely this year from that lull.This year's overheated rally looks like it has run its full course though, progressing even faster than the 2017/2018 gain. Although it's not past the point of no return yet, the action since late July suggests the bears are taking their shot. They've been nice enough to leave clear clues. * Click to EnlargeThe biggest clue to speak of is the converging wedge shape that's formed since July. The lower boundary, plotted in blue, traces all the lows going back to December's low. * Although not overwhelmingly so, the volume tide has started to lean bearishly. Should the Chaikin line on the weekly chart fall under zero, that may be the proverbial tipping point. * As for a plausible downside target, the past two major setbacks have pulled Microsoft shares just below the 200-day moving average line, marked in white on both stock charts. Merck (MRK)Shares of drugmaker Merck have dished out a healthy, even if at times uneven, rally over the course of the past year and a half. Even factoring in the current lull, MRK stock is still up 56% from its early 2018 low.The complexion of that advance has slowly but surely -- maybe even imperceptibly -- taken a turn for the worst though. While still seemingly in bullish mode, the momentum is fading and the pokes at key technical floors are more frequent and more potent. * 7 Tech Stocks You Should Avoid Now * Click to EnlargeThe slowdown of the advance is easily indicated on the daily chart, with each resistance line, marked in yellow, plotted at a shallower direction than the prior one. * It's not a detail even the most focused of chart watchers would notice or care about, but each peak of the Chaikin line since the beginning of this year has been lower than the past, underscoring the slowdown. Ditto for the MACD crossunders. * So far the 200-day moving average line, marked in white on both stock charts, has held up as a floor. The straight-line support that tags all the key lows since early 2018, however, was tested again last week. That's the make-or-break level, marked as a dashed blue line on the weekly chart. Facebook (FB)It's interesting. All stock charts demonstrate some degree of interplay with their moving average. Sometimes it means a lot, and sometimes it means little. It's something that at the very least has to be respected though.To that end, Facebook has been strangely responsive to its moving average line, sometimes being stopped and reversed at them, and other times being blasted past them when they're passed. That's what makes the past couple of weeks so curious … and a little bearish. * Click to EnlargeThe chief worry here is how FB stock tested but failed to hurdle the 50-day moving average line, plotted in purple on both stock charts, this month. As the daily chart shows, the 50-day line has been a biggie. * That being said, there are still a couple of other, albeit less meaningful, moving average lines that have been boundaries in the past that could become a boundary again. * Fueling the prospect of more downside is the fact that, over the long haul, FB stock is no stranger to major moves. The stock is still closer to being overbought than not from this year's rebound move, as indicated by the weekly chart's RSI tool.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about him at his website jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Recession-Resistant Services Stocks to Buy * 7 Hot Penny Stocks to Consider Now * 7 Tech Stocks You Should Avoid Now The post 3 Big Stock Charts for Monday: Merck, Facebook and Microsoft appeared first on InvestorPlace.
- GlobeNewswire
BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia
BERKELEY, Calif., Sept. 16, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in.
- Zacks
Roche's New Perjeta Combo Meets Goal in Breast Cancer Study
Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
- Zacks
Renal Cell Carcinoma Space in Focus: Some Key Developments
The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
- Zacks
Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised)
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
- Investing.com
Stocks - Broadcom, Merck Fall in Premarket; Amazon Rises
Investing.com - Stocks in focus in premarket trading on Friday:
- GuruFocus.com
Gilead Tops List of Most Innovative Drug Companies
Index ranks ability of pharma companies to bring drugs from early testing to market and make them successful Continue reading...
- Reuters
Reuters asks judge to release secret Propecia documents
Reuters asked a U.S. judge on Thursday to unseal documents filed in court regarding potential risks associated with Propecia, Merck & Co's popular baldness drug. The motion was filed in federal court in Brooklyn, New York, after a Reuters article on Wednesday revealed accusations that Merck did not fully disclose on Propecia’s label the incidence and duration of sexual dysfunction in men who took Propecia in clinical trials.
- Zacks
Momentum ETFs & Stocks in Focus as Trump Delays Tariff Hike
While the broader stock market is expected to move higher, momentum investing will likely take charge as investors seek higher returns in a short span.
- Zacks
Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus
Shares of Horizon Therapeutics (HZNP) have gained year to date, owing to its focus on label expansions and pipeline development.
- Zacks
Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.
- Zacks
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
Merck (MRK) closed the most recent trading day at $82.92, moving +1.51% from the previous trading session.
- Zacks
Bristol-Myers' (BMY) Opdivo Shows Long-Term Survival Benefit
Bristol-Myers' (BMY) Opdivo continues to experience long-term OS benefit as demonstrated by the long-term pooled efficacy and safety results in patients with previously-treated NSCLC.
- Zacks
4 Big Drugmakers Boasting Impressive Oncology Pipelines
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
- Zacks
Merck Sees Hammer Chart Pattern: Time to Buy?
Merck & Co. has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks
The Zacks Analyst Blog Highlights: Microsoft, Merck, Procter & Gamble, United Technologies and Coca-Cola
The Zacks Analyst Blog Highlights: Microsoft, Merck, Procter & Gamble, United Technologies and Coca-Cola
- TheStreet.com
Merck Shares Could Trade Sideways Before Renewed Gains
During Tuesday night's Mad Money program, Jim Cramer looked closer at drug maker Merck & Co. which had been riding high on the success of its newest cancer drug, Keytruda. Cramer said Merck is a buy, given the company's strong balance sheet and bountiful dividend yield that pays more than Treasuries. In this daily bar chart of MRK, below, we can see the recent sharp downward move in prices.
- Reuters
Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane
Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation. Novartis last week won the breakthrough therapy tag, which puts it on a fast track for regulatory review, for its capmatinib drug. Pfizer's Xalkori drug was given the designation https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_new_indications-0 last year.
- PR Newswire
Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small ...
- PR Newswire
Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small ...
